Epitope-Dependent Pathogenicity of Antibodies Targeting a Major Bullous Pemphigoid Autoantigen Collagen XVII/BP180

J Invest Dermatol. 2016 May;136(5):938-946. doi: 10.1016/j.jid.2015.11.030. Epub 2016 Jan 28.

Abstract

In bullous pemphigoid, the common autoimmune blistering disorder, IgG autoantibodies target various epitopes on hemidesmosomal transmembrane collagen XVII (COL17)/BP180. Antibodies (Abs) targeting the extracellular noncollagenous 16th A domain of COL17 may be pathogenic; however, the pathogenic roles of Abs targeting non-noncollagenous 16th A regions are poorly understood. In this study using a pathogenic and a nonpathogenic monoclonal antibody (mAb) targeting the noncollagenous 16th A domain (mAb TS39-3) and the C-terminus domain (mAb C17-C1), respectively, we show that endocytosis of immune complexes after binding of Abs to cell surface COL17 is a key phenomenon that induces skin fragility. Passive transfer of IgG1 mouse mAb TS39-3 but not mAb C17-C1 induces dermal-epidermal separation in neonatal human COL17-expressing transgenic mice. Interestingly, mAb C17-C1 strongly binds with the dermal-epidermal junction of the recipient mice skin, suggesting that binding of Abs with COL17 is insufficient to induce skin fragility. In cultured normal human epidermal keratinocytes treated with these mAbs, mAb TS39-3 but not mAb C17-C1 internalizes immune complexes after binding with cell surface COL17 via macropinocytosis, resulting in reduced COL17 expression. This study shows that pathogenicity of Abs targeting COL17 is epitope dependent, which is associated with macropinocytosis-mediated endocytosis of immune complexes and finally results in the depletion of COL17 expression in basal keratinocytes.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / pharmacology
  • Autoantigens / immunology
  • Autoantigens / metabolism*
  • Cells, Cultured
  • Collagen Type XVII
  • Disease Models, Animal
  • Epitopes / immunology*
  • Humans
  • Immunotherapy / methods*
  • Keratinocytes / cytology
  • Mice
  • Mice, Transgenic
  • Molecular Targeted Therapy / methods
  • Non-Fibrillar Collagens / immunology
  • Non-Fibrillar Collagens / metabolism*
  • Pemphigoid, Bullous / immunology*
  • Pemphigoid, Bullous / physiopathology*
  • Pemphigoid, Bullous / therapy
  • Random Allocation
  • Sensitivity and Specificity

Substances

  • Antibodies, Monoclonal
  • Autoantigens
  • Epitopes
  • Non-Fibrillar Collagens